AcelRx Tries Transparency To Reassure Investors After Zalviso ‘Complete Response’
This article was originally published in The Pink Sheet Daily
Executive Summary
Trying to beat The Medicines Co. to market with a patient-administered post-surgical pain analgesic, AcelRx hopes it can re-file the NDA for Zalviso by the end of 2014, based on already filed amendments and adjustments to the delivery mechanism and instructions for use.
You may also be interested in...
AcelRx’s Pain Drug Zalviso Delayed By Delivery Device Issues
FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.